atezolizumab

Showing 7 posts of 7 posts found.

rocheshanghai

FDA grants accelerated approval for Roche’s bladder cancer immunotherapy Tecentriq

May 19, 2016
Research and Development, Sales and Marketing FDA, Roche, atezolizumab, bladder cancer, immunotherapy, tecentriq

Roche (SIX: RO) has announced that the US Food and Drug Administration (FDA) has granted accelerated approval for Tecentriq (atezolizumab) …

roche__tree

Roche’s cancer immunotherapy for lung cancer gets US FDA priority review

April 11, 2016
Business Services, Research and Development, Sales and Marketing Roche, US FDA, atezolizumab, lung cancer

Swiss drug firm Roche (SIX: ROG) on Monday said the US Food and Drug Administration (FDA) has accepted its Biologics …

cancer_cells

Darzalex to be trialled in combination with atezolizumab in multiple myeloma and solid tumours

March 22, 2016
Research and Development Genentech, Genmab, Janssen, Roche, atezolizumab, clnical trials, multiple myeloma, phase ib, solid tumours, tumour

Phase Ib clinical studies are set to begin, which will evaluate Darzalex (daratumumab) in combination with atezolizumab in a solid …

Genentech cancer immunotherapy gets Priority FDA Review in bladder cancer

March 15, 2016
Manufacturing and Production, Research and Development FDA, Genentech, Roche, atezolizumab, bladder cancer, priority review

The US FDA has granted Roche subsidiary Genentech a Priority Review for atezolizumab in treating advanced bladder cancer, whose disease …

Roche building

Roche presents new data for advanced bladder cancer immunotherapy

January 8, 2016
Medical Communications, Research and Development Roche, atezolizumab, bladder cancer

Roche has announced updated results from a pivotal Phase II study, showing its investigational cancer immunotherapy atezolizumab extended median progression …

Chest x ray

Roche lung cancer therapy succeeds in mid-stage trial

August 17, 2015
Research and Development, Sales and Marketing Genentech, Roche, atezolizumab, lung cancer, non-small cell lung cancer

Roche’s biotech arm Genentech has scored positive results in a pivotal Phase II study of its investigational cancer immunotherapy atezolizumab. …

roche__tree

Roche posts positive mid-stage trial results for atezolizumab

July 13, 2015
Research and Development Genentech, PD-L1, Phase II, Roche, anti-PD-L1, atezolizumab, clinical trial, immuno-oncology, personalised medicine

A cancer drug in development by Roche has performed well in a mid-phase clinical trial – prompting the Swiss firm …

The Gateway to Local Adoption Series

Latest content